BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 21421542)

  • 1. Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study.
    Martín M; Sánchez-Rovira P; Muñoz M; Baena-Cañada JM; Mel JR; Margeli M; Ramos M; Martínez E; García-Saenz JA; Casado A; Jaén AM; González-Farré X; Escudero MJ; Rodriguez-Martin C; Carrasco E;
    Ann Oncol; 2011 Dec; 22(12):2591-2596. PubMed ID: 21421542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
    Chia S; Clemons M; Martin LA; Rodgers A; Gelmon K; Pond GR; Panasci L
    J Clin Oncol; 2006 Jun; 24(18):2773-8. PubMed ID: 16682726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.
    Stickeler E; Klar M; Watermann D; Geibel A; Földi M; Hasenburg A; Gitsch G
    Breast Cancer Res Treat; 2009 Oct; 117(3):591-8. PubMed ID: 19156515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial.
    Pircher M; Mlineritsch B; Fridrik MA; Dittrich C; Lang A; Petru E; Weltermann A; Thaler J; Hufnagl C; Gampenrieder SP; Rinnerthaler G; Ressler S; Ulmer H; Greil R
    Anticancer Res; 2015 Jan; 35(1):517-21. PubMed ID: 25550597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer.
    Andreopoulou E; Gaiotti D; Kim E; Volm M; Oratz R; Freedberg R; Downey A; Vogel CL; Chia S; Muggia F
    Clin Breast Cancer; 2007 Aug; 7(9):690-6. PubMed ID: 17919349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation.
    Christodoulou C; Kostopoulos I; Kalofonos HP; Lianos E; Bobos M; Briasoulis E; Gogas H; Razis E; Skarlos DV; Fountzilas G;
    Oncology; 2009; 76(4):275-85. PubMed ID: 19262067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac safety of adjuvant pegylated liposomal doxorubicin with concurrent trastuzumab: a randomized phase II trial.
    Rayson D; Suter TM; Jackisch C; van der Vegt S; Bermejo B; van den Bosch J; Vivanco GL; van Gent AM; Wildiers H; Torres A; Provencher L; Temizkan M; Chirgwin J; Canon JL; Ferrandina G; Srinivasan S; Zhang L; Richel DJ
    Ann Oncol; 2012 Jul; 23(7):1780-8. PubMed ID: 22056854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
    Farhat F; Kattan JG; Ghosn M
    Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198.
    Wolff AC; Wang M; Li H; Pins MR; Pretorius FJ; Rowland KM; Sparano JA; Davidson NE
    Breast Cancer Res Treat; 2010 May; 121(1):111-20. PubMed ID: 20333545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.
    Dang C; Lin N; Moy B; Come S; Sugarman S; Morris P; Abbruzzi A; Chen C; Steingart R; Patil S; Norton L; Winer E; Hudis C
    J Clin Oncol; 2010 Jun; 28(18):2982-8. PubMed ID: 20479410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide.
    Kelly H; Kimmick G; Dees EC; Collichio F; Gatti L; Sawyer L; Ivanova A; Dressler L; Graham ML; Carey LA
    Clin Breast Cancer; 2006 Aug; 7(3):237-43. PubMed ID: 16942640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.
    Baselga J; Manikhas A; Cortés J; Llombart A; Roman L; Semiglazov VF; Byakhov M; Lokanatha D; Forenza S; Goldfarb RH; Matera J; Azarnia N; Hudis CA; Rozencweig M
    Ann Oncol; 2014 Mar; 25(3):592-598. PubMed ID: 24401928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.
    Wang R; Smyth LM; Iyengar N; Chandarlapaty S; Modi S; Jochelson M; Patil S; Norton L; Hudis CA; Dang CT
    Oncologist; 2019 Aug; 24(8):e646-e652. PubMed ID: 30602614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.
    Krop IE; Suter TM; Dang CT; Dirix L; Romieu G; Zamagni C; Citron ML; Campone M; Xu N; Smitt M; Gianni L
    J Clin Oncol; 2015 Apr; 33(10):1136-42. PubMed ID: 25713436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician's choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer.
    Miller K; Cortes J; Hurvitz SA; Krop IE; Tripathy D; Verma S; Riahi K; Reynolds JG; Wickham TJ; Molnar I; Yardley DA
    BMC Cancer; 2016 Jun; 16():352. PubMed ID: 27259714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pegylated liposomal doxorubicin (Lipo-Dox®) combined with cyclophosphamide and 5-fluorouracil is effective and safe as salvage chemotherapy in taxane-treated metastatic breast cancer: an open-label, multi-center, non-comparative phase II study.
    Rau KM; Lin YC; Chen YY; Chen JS; Lee KD; Wang CH; Chang HK
    BMC Cancer; 2015 May; 15():423. PubMed ID: 25994543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification.
    Saracchini S; Foltran L; Tuccia F; Bassini A; Sulfaro S; Micheli E; Del Conte A; Bertola M; Gion M; Lorenzon M; Tumolo S
    Breast; 2013 Dec; 22(6):1101-7. PubMed ID: 24074879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of pegylated liposomal doxorubicin-cyclophosphamide combination as first-line chemotherapy in older metastatic breast cancer patients.
    Kurtz JE; Rousseau F; Meyer N; Delozier T; Serin D; Nabet M; Djafari L; Dufour P
    Oncology; 2007; 73(3-4):210-4. PubMed ID: 18424884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I/II trial of non-pegylated liposomal doxorubicin, docetaxel and trastuzumab as first-line treatment in HER-2-positive locally advanced or metastatic breast cancer.
    Amadori D; Milandri C; Comella G; Saracchini S; Salvagni S; Barone C; Bordonaro R; Gebbia V; Barbato A; Serra P; Gattuso D; Nanni O; Baconnet B; Gasparini G
    Eur J Cancer; 2011 Sep; 47(14):2091-8. PubMed ID: 21665463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegylated liposomal doxorubicin (Duomeisu
    Jiang H; Li H; Song G; Di L; Shao B; Yan Y; Liu X; Chen Y; Zhang R; Ran R; Liu Y; Gui X; Wang N; Wang H
    Breast Cancer Res Treat; 2023 May; 199(1):67-79. PubMed ID: 36877215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.